Granuflo Lawsuit

Text-only Preview


Granuflo Lawsuit
Manufactured by German manufacturer, Fresenius (FMC), GranuFlo is a dialysis product that is
used to clean the blood of patients undergoing hemodialysis for treatment of renal (kidney)
failure. GranuFlo is used by more than a third of the estimated 400,000 hemodialysis patients at
over 5700 dialysis centers in the United States. The FDA began an investigation into Fresenius
products Granuflo Lawsuit and Naturalize, a sister drug, after an internal memo dated November
4, 2011, was leaked.
This memo, sent only to the physicians and clinics that were associated with Fresenius,
confirmed the significant risk of cardiopulmonary arrest and death among patients undergoing
dialysis treatment. This was due to an incorrect dialysis concentration. According to this memo,
941 patients treated at FMC clinics had suffered cardiac arrest during or shortly after treatment
with GranuFlo. GranuFlo is administered at dialysis clinics all over the United States both FMC
affiliated and non FMC clinics.
GranuFlo is the only dialysis solution product containing the powdered form of acetic acid
(sodium diacetate). This powered form is desired by the clinics as it allows them to mix their
own dialysate solution as well as avoiding the higher shipping costs of the 55 gallon drums of
pre-mixed solution. Dialysis Heart Attack is the only dialysis solution product containing the
powdered form of acetic acid (sodium diacetate). This powered form is desired by the clinics as
it allows them to mix their own dialysate solution as well as avoiding the higher shipping costs
of the 55 gallon drums of pre-mixed solution.

You Can Get More Information Here: Dialysis Injury